UBS Group
LEGN icon

UBS Group’s Legend Biotech LEGN Stock Holding History

UBS Group’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.5M Buy
502,466
+197,252
+65% +$5.32M ﹤0.01% 3026
2026
Q1 		$5.52M Buy
305,214
+80,602
+36% +$1.54M ﹤0.01% 3983
2025
Q4 		$4.88M Sell
224,612
-786,247
-78% -$22.5M ﹤0.01% 4054
2025
Q3 		$33M Sell
1,010,859
-10,697
-1% -$395K 0.01% 2040
2025
Q2 		$36.3M Buy
1,021,556
+60,381
+6% +$1.96M 0.01% 1808
2025
Q1 		$32.6M Sell
961,175
-18,863
-2% -$676K 0.01% 1883
2024
Q4 		$31.9M Buy
980,038
+861,920
+730% +$35.7M 0.01% 1867
2024
Q3 		$5.76M Sell
118,118
-1,521
-1% -$81K ﹤0.01% 2934
2024
Q2 		$5.3M Sell
119,639
-8,477
-7% -$391K ﹤0.01% 2826
2024
Q1 		$7.19M Sell
128,116
-171,127
-57% -$10.3M ﹤0.01% 2583
2023
Q4 		$18M Sell
299,243
-2,332
-0.8% -$148K 0.01% 1650
2023
Q3 		$20.3M Buy
301,575
+160,446
+114% +$11.1M 0.01% 1470
2023
Q2 		$9.74M Sell
141,129
-2,437
-2% -$159K ﹤0.01% 1979
2023
Q1 		$6.92M Buy
143,566
+33,509
+30% +$1.64M ﹤0.01% 2215
2022
Q4 		$5.49M Buy
110,057
+11,766
+12% +$570K ﹤0.01% 2412
2022
Q3 		$4.01M Buy
98,291
+9,761
+11% +$458K ﹤0.01% 2556
2022
Q2 		$4.87M Sell
88,530
-13,065
-13% -$552K ﹤0.01% 2399
2022
Q1 		$3.69M Sell
101,595
-809
-0.8% -$32K ﹤0.01% 2840
2021
Q4 		$4.77M Buy
102,404
+45,748
+81% +$2.32M ﹤0.01% 2874
2021
Q3 		$2.86M Buy
56,656
+54,366
+2,374% +$2.26M ﹤0.01% 3248
2021
Q2 		$94K Buy
2,290
+433
+23% +$14.7K ﹤0.01% 5930
2021
Q1 		$54K Sell
1,857
-113
-6% -$3.08K ﹤0.01% 6465
2020
Q4 		$55K Buy
1,970
+802
+69% +$23.1K ﹤0.01% 6098
2020
Q3 		$36K Buy
1,168
+668
+134% +$22.5K ﹤0.01% 5863
2020
Q2 		$21K Buy
+500
New +$19.5K ﹤0.01% 6523

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

UBS Group's LEGN Position: Q2 2026 in Review

UBS Group increased its Legend Biotech (LEGN) stake by 65% in Q2 2026, buying an estimated $5.32M and bringing the position to 502,466 shares worth $14.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3026.

UBS Group first reported a position in LEGN in Q2 2020 and has held it in 25 quarters since. The position peaked at $36.3M in Q2 2025. 218 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • UBS Group held 502,466 shares of Legend Biotech worth $14.5M as of Q2 2026.
  • UBS Group bought 197,252 Legend Biotech shares in Q2 2026, an estimated $5.32M.
  • Legend Biotech made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3026 holding.
  • UBS Group first reported a position in Legend Biotech in Q2 2020 and has held it in 25 quarters since.
  • UBS Group's Legend Biotech position peaked at $36.3M in Q2 2025.
  • 218 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.